Abstract:Tumor heterogeneity results in more than 50% of hypermutated cancers failing to respond to standard immunotherapy. There are numerous challenges in terms of drug resistance, therapeutic strategies, and biomarkers in immunotherapy. In this study, we analyzed primary tumor samples from 533 cancer patients with six different cancer types using deep targeted sequencing and gene expression data from 78 colorectal cancer patients, whereby driver mutations, mutational signatures, tumor-associated neoantigens, and molecular cancer evolution were investigated. Driver mutations, including RET, CBL, and DDR2 gene mutations, were identified in the hypermutated cancers. Most hypermutated endometrial and pancreatic cancer patients carry genetic mutations in EGFR, FBXW7, and PIK3CA that are linked to immunotherapy resistance, while hypermutated head and neck cancer patients carry genetic mutations associated with better treatment responses, such as ATM and BRRCA2 mutations. APOBEC (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like) and DNA repair defects are mutational drivers that are signatures for hypermutated cancer. Cancer driver mutations and other mutational signatures are associated with sensitivity or resistance to immunotherapy, representing potential genetic markers in hypermutated cancers. Using computational prediction, we identified NF1 p.T700I and NOTCH1 p.V2153M as tumor-associated neoantigens, representing potential therapeutic targets for immunotherapy. Sequential mutations were used to predict hypermutated cancers based on genomic evolution. Using a logistic model, we achieved an area under the curve (AUC) = 0.93, accuracy = 0.93, and sensitivity = 0.81 in the testing set. The sequential patterns were distinct among the six cancer types, and the sequential mutation order of MSH2 and the coexisting BRAF genetic mutations influenced the hypermutated phenotype. The TP53~MLH1 and NOTCH1~TET2 sequential mutations impacted colorectal cancer survival (p-value = 0.027 and 0.0001, respectively) by reducing the expression of PTPRCAP (p-value = 1.06 × 10−6) and NOS2 (p-value = 7.57 × 10−7) in immunity. Sequential mutations are significant for hypermutated cancers, which are characterized by mutational heterogeneity. In addition to driver mutations and mutational signatures, sequential mutations in cancer evolution can impact hypermutated cancers. They characterize potential responses or predictive markers for hypermutated cancers. These data can also be used to develop hypermutation-associated drug targets and elucidate the evolutionary biology of cancer survival. In this study, we conducted a comprehensive analysis of mutational patterns, including sequential mutations, and identified useful markers and therapeutic targets in hypermutated cancer patients.

An Analysis of Mutational Signatures of Synonymous Mutations Across 15 Cancer Types.

Nucleotide-Based Significance of Somatic Synonymous Mutations for Pan-Cancer

Incorporating mutational heterogeneity to identify genes that are enriched for synonymous mutations in cancer

Genome-wide Mutational Spectra Analysis Reveals Significant Cancer-Specific Heterogeneity

Somatic synonymous mutations in regulatory elements contribute to the genetic aetiology of melanoma

Pan-cancer analyses of synonymous mutations based on tissue-specific codon optimality

Mutational landscape and significance across 12 major cancer types

Synonymous mutations that regulate translation speed might play a non-negligible role in liver cancer development

Association of mutation signature effectuating processes with mutation hotspots in driver genes and non-coding regions

Nonsynonymous, Synonymous and Nonsense Mutations in Human Cancer-Related Genes Undergo Stronger Purifying Selections Than Expectation

Synonymous Mutations In Oncogenesis And Apoptosis Versus Survival Unveiled By Network Modeling

Abstract 5722: The mutational signatures of 100,477 targeted sequenced tumors

Therapeutic and Prognostic Insights from the Analysis of Cancer Mutational Signatures

Prevalence and Architecture of Posttranscriptionally Impaired Synonymous Mutations in 8,320 Genomes Across 22 Cancer Types.

A global transcriptional network connecting noncoding mutations to changes in tumor gene expression

Protein structural context of cancer mutations reveals molecular mechanisms and identifies novel candidate driver genes

Mutational signatures and their association with cancer survival and gene expression in multiple cancer types

Signatures of mutational processes in human cancer

The shaping of cancer genomes with the regional impact of mutation processes

Comprehensively Exploring the Mutational Landscape and Patterns of Genomic Evolution in Hypermutated Cancers

Remarkable Difference of Somatic Mutation Patterns Between Oncogenes and Tumor Suppressor Genes.